Victrex/£VCT

08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX

About Victrex

Victrex PLC, founded in 1993 and headquartered in Thornton Cleveleys, UK, is a company that specializes in the manufacturing of high-performance polymeric solutions. It operates in the Specialty Chemicals sector within the materials industry, offering products made primarily from PEEK and PAEK-based materials used in a wide range of sectors including automotive, aerospace, energy, electronics, and medical. Its operations focus on both the development and production of these advanced polymer solutions, catering to both industrial and medical applications across various global markets.

Ticker

£VCT
Sector

Primary listing

LSE

Employees

1,131

Victrex Metrics

BasicAdvanced
£538M
18.03
£0.34
0.65
£0.60
9.72%

What the Analysts think about Victrex

Analyst ratings (Buy, Hold, Sell) for Victrex stock.

Bulls say / Bears say

Sales volume rose 8% to 1 057 tonnes in Q3, driven by strong growth in Sustainable Solutions, Energy & Industrial and VARs, underscoring resilient end-market demand (RTTNews).
Victrex announced the appointment of Dr James Routh as CEO effective 1 January 2026, ensuring leadership continuity and potential strategic renewal following the current CEO’s departure (TradingView).
In Q1 to 31 December 2024, revenue grew 8.5% to £66.6 million and volumes jumped 18% to 898 tonnes, while full-year guidance for mid-single-digit volume growth was maintained, demonstrating robust early-year momentum (Alliance News).
Q3 revenue fell 3% year-on-year to £71.5 million, driven primarily by weaker medical sales, leading to a 9% drop in the stock price on the update day (RTTNews).
Average selling prices (ASP) declined 11% in Q3 to £68 per kg, reflecting adverse sales mix and pricing pressure that weighed on margins despite higher volumes (Research-Tree).
Continuing softness in the Medical division, exacerbated by customer destocking and a £7–8 million currency headwind to pretax profit, has skewed expected profit growth to the second half of the year (Alliance News).
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.

Victrex Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Victrex Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £VCT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Victrex stock | £VCT Share Price | Lightyear